| Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Clinical Microbiology and Infection | ||||
| Verlag: | ELSEVIER SCI LTD | ||||
| Ort der Veröffentlichung: | OXFORD | ||||
| Band: | 29 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 2 | ||||
| Seitenbereich: | S. 200-207 | ||||
| Datum: | 2023 | ||||
| Institutionen: | Medizin > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien Medizin > Abteilung für Krankenhaushygiene und Infektiologie Medizin > Notfallambulanz | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | PRIMER; Bloodstream infection; Daptomycin; Mortality; Relapse; Vancomycin-resistant Enterococcus; Linezolid | ||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Ja | ||||
| Dokumenten-ID: | 75721 |
Web of ScienceZusammenfassung
Objectives: The optimal treatment duration for vancomycin-resistant enterococcal (VRE) bacteraemia is still a matter of debate. The aim of the present study was to compare short-course (<= 9 days) and long -course (>= 10 days) antibiotic treatments in hospitalized adult patients with uncomplicated VRE bacteraemia. Methods: This retrospective study was conducted in four university hospitals in ...
Zusammenfassung
Objectives: The optimal treatment duration for vancomycin-resistant enterococcal (VRE) bacteraemia is still a matter of debate. The aim of the present study was to compare short-course (<= 9 days) and long -course (>= 10 days) antibiotic treatments in hospitalized adult patients with uncomplicated VRE bacteraemia. Methods: This retrospective study was conducted in four university hospitals in Germany. Adult patients with a positive blood culture for a VRE were screened from 1 January 2016 to 31 December 2018. Only patients who received a VRE-active antibiotic for at least 48 hours were included. The exclusion criteria were a survival of <10 days and a deep-seated source of infection requiring prolonged treatment. To compare the outcome of short-course therapy with that of long-course therapy, 30-day and 90-day overall mortality, relapse within 90 days, duration of hospitalization, and potential antibiotic-related adverse events were analysed by inverse probability of treatment weighting using the propensity score and by additional covariate adjustment. Results: Of the 363 patients screened, 219 (60.3%) patients were included in the final analysis. Among them, 48 (21.9%) patients had underlying haematological diseases. Seventy-eight (35.6%) patients received short-course treatment (median, 7 days; interquartile range, 5-8 days) and 141 (64.4%) patients received long-course treatment (median, 15 days; interquartile range, 12-23.5 days). Thirty-day mor-tality was similar in both groups (19.2% vs. 22.0%; adjusted OR, 1.15; p 0.773). Duration of hospitalization (in total and after onset of bacteraemia) was significantly shorter (p < 0.05) in the short-course treatment group, whereas other secondary outcome parameters did not differ between both groups. Discussion: Our study suggests that short-course treatment might not be associated with a worse outcome in patients with uncomplicated VRE bacteraemia. Christina Bahrs, Clin Microbiol Infect 2023;29:200 (c) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Metadaten zuletzt geändert: 18 Mrz 2025 10:04
Altmetric